Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells $654,807.42 in Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) COO Kathleen Goin sold 4,302 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $152.21, for a total transaction of $654,807.42. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathleen Goin also recently made the following trade(s):

• On Wednesday, June 17th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46.

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock traded down $7.38 during trading on Thursday, hitting $142.58. The company’s stock had a trading volume of 208,989 shares, compared to its average volume of 270,510. Palvella Therapeutics, Inc. has a 52 week low of $48.65 and a 52 week high of $161.38. The company has a market capitalization of $2.05 billion, a PE ratio of -29.52 and a beta of -0.17. The company has a fifty day simple moving average of $140.96 and a two-hundred day simple moving average of $123.87.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, analysts predict that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on PVLA shares. Stephens restated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Canaccord Genuity Group set a $232.00 target price on Palvella Therapeutics in a research note on Wednesday, August 5th. Chardan Capital upgraded Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Finally, Truist Financial set a $207.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Palvella Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $209.14.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently made changes to their positions in PVLA. KBC Group NV bought a new position in Palvella Therapeutics during the first quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in Palvella Therapeutics in the 2nd quarter worth approximately $35,000. Group One Trading LLC grew its position in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. purchased a new stake in Palvella Therapeutics during the 3rd quarter valued at $36,000. Finally, Archer Investment Corp purchased a new stake in Palvella Therapeutics during the 2nd quarter valued at $69,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.